“I very much look forward to working with Dr. Sampson to diligently advance our clinical trial program for brain tumors with the vision of bringing a new and effective treatment option to adult and pediatric patients with recurrent or refractory high grade gliomas, including pediatric patients with diffuse intrinsic pontine glioma (DIPG) (WHO Grade IV) who are in urgent need for therapeutic innovations.” said Dr.
Dr. Sampson received his M.D. from the
Dr. Sampson is a recognized leader in the surgical resection and experimental treatment of complex brain tumors. His clinical practice is focused on treating patients with both benign and malignant brain tumors, while his research laboratory is actively investigating immunotherapy and new modalities of precision drug delivery to brain tumor tissue while avoiding healthy tissue. He is a neurosurgeon-scientist who develops novel drugs for patients with brain tumors and focuses on the development, translation, and mechanistic understanding of immunotherapies. His research led to the development of a vaccine against a common mutation in brain tumors that was given Breakthrough Therapy Designation by the
Oncotelic is a wholly owned subsidiary of
About Oncotelic’s Lead Product Candidate, OT-101
High-grade gliomas (HGG) are characterized by a T-cell exhaustion signature and pronounced T-cell hyporesponsiveness of their tumor microenvironment (TME). Transforming growth factor beta 2 (TGFB2) has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG. OT-101, a TGFB2-specific first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of TGFB2. In a completed Phase 2 clinical study, OT-101 exhibited clinically meaningful single-agent activity and induces durable complete and partial responses in recurrent and refractory adult HGG patients, including young adults with GBM or AA.
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, "estimate," "intend," "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the
Source: Mateon Therapeutics